We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

SK:EURONEXT PARISSEB SA Analysis

Data as of 2026-05-29 - not real-time

$38.52

Latest Price

8/10Risk

Risk Level: High

Executive Summary

SkyWater Technology (SK) is trading well above its short‑term moving averages, indicating strong momentum. The RSI is approaching overbought territory, suggesting limited upside. MACD remains bullish with the line above its signal, reinforcing the upward bias. Trading volume has been tapering, which could foreshadow a slowdown in price acceleration. A high beta and elevated 30‑day volatility underscore a highly volatile profile. Fundamentally, revenue has surged dramatically year‑over‑year, but operating margins are negative and cash flow is strained.
The company carries a debt‑to‑equity ratio that is markedly high, indicating significant leverage risk. The DCF‑derived fair value is far below the current market price, implying the stock is materially overvalued. While the sector’s average P/E is much higher than SKYT’s, the price‑to‑book ratio remains elevated, raising concerns about balance‑sheet quality. Recent shareholder approval news provides a neutral catalyst but does not materially shift the valuation picture. The “Extreme Greed” sentiment index reflects market euphoria that may be unsustainable. Overall, the combination of bullish technicals and weak fundamentals suggests caution, with a bias toward holding or trimming exposure.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • price above short‑term moving averages
  • RSI near overbought but MACD bullish
  • decreasing volume suggests potential pullback

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • revenue growth outpacing peers
  • high leverage and negative cash flow
  • stock trading well above DCF fair value

Long Term

> 3 years
Cautious
Model confidence: 7/10

Key Factors

  • sector cyclicality and high beta
  • balance‑sheet weakness with high debt
  • lack of dividend and earnings volatility

Key Metrics & Analysis

Financial Health

Revenue Growth162.10%
Profit Margin21.04%
P/E Ratio16.5
ROE95.85%
ROA-0.45%
Debt/Equity126.86
P/B Ratio10.0
Op. Cash Flow$-57033000
Free Cash Flow$35.9M
Industry P/E41.7

Technical Analysis

TrendBullish
RSI69.9
Support$31.33
Resistance$39.28
MA 20$35.27
MA 50$32.12
MA 200$23.43
MACDBullish
VolumeDecreasing
Fear & Greed Index94.21

Valuation

Fair Value$21.92
Target Price$35.00
Upside/Downside-9.13%
GradeOvervalued
TypeGrowth

Risk Assessment

Beta2.81
Volatility39.90%
Sector RiskHigh
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.